Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
…, EF Smit, C Faivre-Finn, TS Mok, M Reck… - Annals of …, 2018 - annalsofoncology.org
Primary lung cancer remains the most common malignancy after non-melanocytic skin cancer,
and deaths from lung cancer exceed those from any other malignancy worldwide [1]. In …
and deaths from lung cancer exceed those from any other malignancy worldwide [1]. In …
First-line immunotherapy for non–small-cell lung cancer
M Reck, J Remon, MD Hellmann - Journal of Clinical Oncology, 2022 - ingentaconnect.com
For patients with metastatic non–small-cell lung cancer (mNSCLC), the last decade has been
characterized by critical progress that has contributed to substantially improved survival. In …
characterized by critical progress that has contributed to substantially improved survival. In …
Management of non-small-cell lung cancer: recent developments
Non-small-cell lung cancer is one of the leading causes of deaths from cancer worldwide.
Therefore, improvements in diagnostics and treatments are urgently needed. In this review, we …
Therefore, improvements in diagnostics and treatments are urgently needed. In this review, we …
[HTML][HTML] Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer
M Reck, D Rodríguez-Abreu… - … England Journal of …, 2016 - Mass Medical Soc
Background Pembrolizumab is a humanized monoclonal antibody against programmed
death 1 (PD-1) that has antitumor activity in advanced non–small-cell lung cancer (NSCLC), …
death 1 (PD-1) that has antitumor activity in advanced non–small-cell lung cancer (NSCLC), …
[HTML][HTML] Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer
Background Patients with advanced squamous-cell non–small-cell lung cancer (NSCLC)
who have disease progression during or after first-line chemotherapy have limited treatment …
who have disease progression during or after first-line chemotherapy have limited treatment …
[HTML][HTML] Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer
…, M Reck, R Hui, EB Garon, M Boyer… - New England journal …, 2018 - Mass Medical Soc
Background First-line therapy for advanced non–small-cell lung cancer (NSCLC) that lacks
targetable mutations is platinum-based chemotherapy. Among patients with a tumor …
targetable mutations is platinum-based chemotherapy. Among patients with a tumor …
[HTML][HTML] Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC
…, A Lopez-Chavez, A Sandler, M Reck - … England Journal of …, 2018 - Mass Medical Soc
Background The cancer-cell–killing property of atezolizumab may be enhanced by the blockade
of vascular endothelial growth factor–mediated immunosuppression with bevacizumab. …
of vascular endothelial growth factor–mediated immunosuppression with bevacizumab. …
[HTML][HTML] First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer
…, ML Johnson, M Nishio, M Reck… - … England Journal of …, 2018 - Mass Medical Soc
Background Enhancing tumor-specific T-cell immunity by inhibiting programmed death ligand
1 (PD-L1)–programmed death 1 (PD-1) signaling has shown promise in the treatment of …
1 (PD-L1)–programmed death 1 (PD-1) signaling has shown promise in the treatment of …
[HTML][HTML] First-line nivolumab in stage IV or recurrent non–small-cell lung cancer
DP Carbone, M Reck, L Paz-Ares… - … England Journal of …, 2017 - Mass Medical Soc
Background Nivolumab has been associated with longer overall survival than docetaxel
among patients with previously treated non–small-cell lung cancer (NSCLC). In an open-label …
among patients with previously treated non–small-cell lung cancer (NSCLC). In an open-label …
[HTML][HTML] Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC
…, C Faivre-Finn, M Reck… - … England Journal of …, 2018 - Mass Medical Soc
Background An earlier analysis in this phase 3 trial showed that durvalumab significantly
prolonged progression-free survival, as compared with placebo, among patients with stage III, …
prolonged progression-free survival, as compared with placebo, among patients with stage III, …